Hims & Hers Health (HIMS) Change in Accured Expenses (2019 - 2026)
Hims & Hers Health (HIMS) reported Change in Accured Expenses of $10.0 million for Q1 2026, up 130.2% on a YoY basis from $4.4 million in Q1 2025, and up 625.22% sequentially from -$1.9 million in Q4 2025.
Hims & Hers Health (HIMS) Change in Accured Expenses (2019 - 2026) Analysis & Trends
Hims & Hers Health (HIMS) has 8 years of Change in Accured Expenses data on file, last reported at $10.0 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 130.2% year-over-year to $10.0 million; the trailing twelve-month figure through Mar 2026 stood at -$37.4 million (down 222.99% YoY), and the FY2025 full-year result was -$43.1 million, down 280.96% from the prior year.
- Change in Accured Expenses rose to $10.0 million in Q1 2026, from -$1.9 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $14.0 million in Q3 2024 to a low of -$52.9 million in Q3 2025.
- A 5-year average of $481588.2 and a median of $3.3 million in 2022 frame the typical range for Change in Accured Expenses.
- Across the five-year window, Change in Accured Expenses slumped 565.29% in 2022 and soared 507.26% in 2024, its largest moves.
- Tracing HIMS's Change in Accured Expenses over 5 years: stood at -$4.6 million in 2022, then surged by 134.96% to $1.6 million in 2023, then soared by 507.26% to $9.8 million in 2024, then slumped by 119.48% to -$1.9 million in 2025, then surged by 625.22% to $10.0 million in 2026.
- Business Quant data shows HIMS's Change in Accured Expenses at $10.0 million in Q1 2026, -$1.9 million in Q4 2025, and -$52.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Hims & Hers Health | 6.44 Bn | 5.69 Bn | 396.79 Mn | 10.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.02 Mn |
| Mar 31, 2026 | 10.02 Mn |
| Dec 31, 2025 | -1.91 Mn |
| Dec 31, 2025 | -1.91 Mn |
| Sep 30, 2025 | -52.88 Mn |
| Sep 30, 2025 | -52.88 Mn |
| Jun 30, 2025 | 7.39 Mn |
| Jun 30, 2025 | 7.39 Mn |
| Mar 31, 2025 | 4.35 Mn |
| Mar 31, 2025 | 4.35 Mn |
| Dec 31, 2024 | 9.79 Mn |
| Dec 31, 2024 | 9.79 Mn |
| Sep 30, 2024 | 14.03 Mn |
| Sep 30, 2024 | 14.03 Mn |
| Jun 30, 2024 | 2.23 Mn |
| Jun 30, 2024 | 2.23 Mn |
| Mar 31, 2024 | -2.26 Mn |
| Mar 31, 2024 | -2.26 Mn |
| Dec 31, 2023 | 1.61 Mn |
| Dec 31, 2023 | 1.61 Mn |